呼吸系统疾病疫苗市场（依疫苗类型、年龄层、通路、最终用户和给药途径划分）－2025-2032年全球预测

预计到 2032 年，呼吸道疾病疫苗市场规模将达到 396.4 亿美元，复合年增长率为 6.04%。

随着流行病学趋同、技术加速发展和医疗卫生系统预期变化，呼吸道疫苗优先事项的策略实施也随之改变。

病原体疫情的持续爆发、冬季发病率的上升以及人们对呼吸系统长期后遗症认识的不断提高，使得全球迫切需要预防和减轻呼吸系统疾病。疫苗学的进步，包括新一代疫苗平台和佐剂科学，正在丰富疾病预防的套件。同时，卫生系统正在重新评估预防、急性治疗和慢性呼吸系统疾病管理等方面的优先事项，促使公共和私营部门开展新的投资和策略合作。

来自临床计画和实际疫苗接种工作的最新证据正在揭示疫苗在哪些方面能够最有效地降低重症率、减轻住院负担并降低更广泛的社会成本。同时，监管审查也在进行调整，以平衡快速审批和严格的安全监测，在确保患者更快获得疫苗的同时，维持上市后监测的核心地位。这种环境要求公共卫生机构、生产商和供应链合作伙伴在平台选择、目标族群和分销物流等优先事项上达成协议。因此，呼吸道疫苗领域正从单一的季节性疾病预防模式转向涵盖流感、SARS样冠状病毒、呼吸道合胞病毒（RSV）以及其他病毒和细菌性呼吸道病原体的多重威胁预防体系。

展望未来，相关人员必须权衡快速的技术进步与生产能力、低温运输物流和公平取得等方面的持续限制因素。因此，策略规划必须整合科学、营运和政策手段，以确保疫苗创新能够转化为可衡量的公共卫生成果，同时避免加剧疫苗取得和供应方面现有的不平等现象。

平台创新、监管现代化和重塑分销模式如何从根本上重塑呼吸道疫苗生态系统和相关人员的策略

呼吸道疫苗领域正因平台创新、监管理念转变以及新型生产和分销商业模式的出现而改变。 mRNA和病毒载体技术的突破性进展缩短了抗原设计的前置作业时间，并实现了能够同时对抗多种病原体和病毒株的多效价构建。这些平台技术的进步，加上佐剂和抗原呈现技术的改进，正在延长免疫反应的持续时间并扩大免疫范围，从而改变疫苗计画的规划和靶向方式。

监管机构正越来越多地采用适应性滚动审查机制，以加快急需疫苗的获取，同时保持严格的核准后监管。因此，生产商正更早投资于后期规模化生产和真实世界证据的收集。创新者与製造外包之间的策略伙伴关係日益增多，同时，为降低供应链脆弱性而对区域生产中心的投资也在增加。

分发模式也在不断演变。传统的季节性疫苗宣传活动正逐渐被综合免疫策略所取代，这些策略考虑了多种分发管道，包括联合接种、针对性加强免疫策略，以及扩大药局和数位管道的作用。资助者、监管机构和采购者越来越呼吁建立透明的分配框架和技术转移机制，以增强本地生产能力。这些因素共同作用，正在重塑呼吸系统疾病预防的科学和商业模式。

评估2025年关税政策变化对疫苗原料采购、生产结构和国际合作动态的连锁反应

征收或调整关税的政策转变可能会对全球疫苗生态系统产生迭加效应，而2025年推出的措施则反映了贸易政策与卫生安全之间的相互影响。对疫苗生产中使用的进口投入品（例如专用试剂、一次性系统和某些组件）征收关税，可能会使采购复杂化，并促使企业重新评估筹资策略。随着时间的推移，此类调整可能会提高下游生产的成本基础，并促使某些生产环节转移，从而造成短期混乱和长期结构性变化。

此外，关税也会影响区域製造地的比较优势。如果关税壁垒提高了市场内企业半成品的到岸成本，则可能促使製造商加快对垂直整合的投资，或重新配置供应链，优先使用本地可获得的投入。虽然这可能增强区域韧性，但也可能减缓新型试剂和平台技术的推广，尤其是对于那些缺乏资金快速重新配置供应链的小型开发商。

主导摩擦也会影响合作研究和许可授权。跨境临床试验和试剂交换可能造成繁琐的行政手续，减缓转化研究过程，并延缓多中心合作。因此，相关人员临着权衡取舍：既要保障国内生产，也要维持历史上加速疫苗研发的开放式创新网络。为此，各公司优先考虑建立库存缓衝、签订双重采购协议以及建立策略伙伴关係关係，以对冲关税波动风险，同时确保快速技术转移和规模化生产的途径。

基于疫苗平台、年龄层、通路、最终用户和给药途径的详细细分洞察，能够实现差异化的研发和交付策略。

细分市场分析揭示了决定疫苗研发、定位和交付方式的多个维度。在疫苗类型方面，相关人员必须考虑结合疫苗、灭活疫苗、减毒活疫苗、mRNA疫苗、次单位疫苗疫苗和病毒载体活病毒疫苗的科学和物流特性，并认识到每种平台对生产复杂性、低温运输要求和免疫抗原性特征都有其独特的影响，因为不同亚组的免疫成熟度和风险效益评估存在显着差异，这些差异体现在给药方案和联合用药策略中。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 整合mRNA技术以加速通用呼吸道合胞病毒疫苗的研发
• 扩大佐剂配方以增强免疫抗原性
• 用于黏膜免疫的下一代鼻腔新冠疫苗的监管进展
• 投资研发针对多种呼吸道病原体的联合疫苗，以简化疫苗接种程序。
• 采用基于奈米颗粒的递送系统来提高儿童呼吸道融合病毒（RSV）疫苗的稳定性和有效性
• 针对新型SARS-CoV-2变种的泛冠状病毒疫苗临床试验取得进展
• 耐热疫苗製剂的出现降低了全球免疫宣传活动低温运输的依赖。
• 政府资助的倡议，旨在支持研发具有广泛保护作用的通用流感疫苗。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 呼吸系统疾病疫苗市场（依疫苗类型划分）

• 结合疫苗
• 灭活疫苗
• 减毒活疫苗
• mRNA疫苗
• 次单位疫苗
• 病毒载体疫苗

9. 按年龄组别分類的呼吸道疾病疫苗市场

• 成人
  • 中年
  • 老年人
  • 青壮年
• 老年人
  • 非常年迈的人
  • 老年人
• 孩子们
  • 青春期
  • 婴儿
  • 婴儿
  • 新生

第十章 呼吸系统疾病疫苗市场（依通路划分）

• 直接购买
• 医院药房
• 网路药局
  • 行动应用程式销售
  • 网站销售
• 零售药局
  • 连锁药局
  • 独立药房

第十一章 呼吸系统疾病疫苗市场（以最终用户划分）

• 诊所
• 居家医疗
• 医院
  • 公立医院
  • 私立医院
• 研究所

12. 呼吸系统疾病疫苗市场依给药途径划分

• 肌肉注射
• 鼻内
• 口服
• 皮下

第十三章 各地区呼吸系统疾病疫苗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 呼吸系统疾病疫苗市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国呼吸系统疾病疫苗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Sanofi SA
  • Seqirus Pty Ltd
  • Moderna, Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Novavax, Inc.
  • BioNTech SE
  • Sinovac BIoTech Co., Ltd.

The Respiratory Disease Vaccine Market is projected to grow by USD 39.64 billion at a CAGR of 6.04% by 2032.

A strategic introduction to respiratory vaccine priorities driven by converging epidemiology, technological acceleration, and shifting health system expectations

The global imperative to prevent and mitigate respiratory disease has intensified as a result of successive pathogen outbreaks, rising wintertime morbidity, and growing recognition of long-term respiratory sequelae. Advances in vaccinology, including next-generation platforms and adjuvant science, have created a more diverse toolkit for disease prevention. At the same time, health systems are reassessing priorities across prevention, acute care, and chronic respiratory management, prompting new investment and strategic collaboration across public and private sectors.

Emerging evidence from clinical programs and real-world immunization initiatives has clarified where vaccines can most effectively reduce severe disease, hospital pressure, and broader societal costs. Concurrently, regulatory pathways have adapted to balance accelerated review with rigorous safety monitoring, enabling more rapid patient access while keeping post-market surveillance central. This environment demands that public health officials, manufacturers, and supply chain partners align on priorities such as platform selection, target populations, and distribution logistics. As a result, the respiratory vaccine landscape is transforming from a narrow seasonal focus into a multi-threat prevention ecosystem that spans influenza, SARS-like coronaviruses, RSV, and other viral and bacterial respiratory pathogens.

Looking forward, stakeholders must reconcile rapid technological progress with persistent constraints in manufacturing capacity, cold-chain logistics, and equitable access. Consequently, strategic planning must integrate scientific, operational, and policy levers to ensure that vaccine innovations translate into measurable public health outcomes without exacerbating existing inequalities in access and delivery.

How platform innovation, regulatory modernization, and distribution model reinvention are fundamentally reshaping the respiratory vaccine ecosystem and stakeholder strategies

The respiratory vaccine landscape is experiencing transformative shifts driven by platform innovation, changes in regulatory philosophy, and new commercial models for manufacture and distribution. Breakthroughs in mRNA and viral vector technologies have reduced lead times for antigen design and enabled multivalent constructs that address several pathogens or strains simultaneously. These platform advances are complemented by improvements in adjuvants and antigen presentation that extend durability and broaden immune responses, thereby altering vaccine program design and target population thinking.

Regulatory authorities have increasingly embraced adaptive and rolling review mechanisms, which facilitate accelerated access for high-need vaccines while maintaining rigorous post-authorization surveillance. As a result, manufacturers are investing earlier in late-stage manufacturing scale-up and real-world evidence generation. In parallel, commercial dynamics are shifting: strategic partnerships between innovators and contract manufacturing organizations are proliferating, while parallel investments in regional production hubs aim to reduce supply chain vulnerability.

Distribution models are also evolving. Traditional seasonal vaccination campaigns are giving way to integrated immunization strategies that consider co-administration, targeted booster strategies, and diversified distribution channels, including expanded roles for pharmacies and digital channels. Finally, equity considerations are drawing sustained attention: funders, regulators, and purchasers are increasingly demanding transparent allocation frameworks and technology transfers to strengthen local manufacturing capacity. Together, these forces are reshaping both the science and the business of respiratory disease prevention.

Evaluating how tariff policy shifts in 2025 exert cascading effects on vaccine input sourcing, manufacturing configurations, and international collaboration dynamics

Policy shifts that introduce or alter tariffs can have a compounding effect on the global vaccine ecosystem, and measures introduced in the United States in 2025 demonstrate how trade policy intersects with health security. Tariffs on imported inputs used in vaccine manufacturing, including specialized reagents, single-use systems, and certain componentry, can increase procurement complexity and prompt firms to reassess sourcing strategies. Over time, such adjustments can raise the cost base for downstream manufacturing and encourage relocation of certain production stages, generating both near-term disruption and longer-term structural change.

Moreover, tariffs can influence the comparative advantage of regional manufacturing hubs. If tariff barriers raise the landed cost of intermediate goods for facilities operating in a given market, manufacturers may accelerate investments in vertical integration or reconfigure supply chains to preferentially source locally available inputs. Although this can strengthen regional resilience, it may also slow the diffusion of novel reagents and platform technologies, particularly for smaller developers who lack the capital to retool supply chains quickly.

Tariff-driven frictions also affect collaborative research and licensing. Cross-border clinical trial operations and reagent exchanges can become administratively heavier, reducing the velocity of translational work and slowing multi-site studies. As a result, stakeholders face trade-offs between insulating domestic manufacturing and preserving the open innovation networks that historically accelerated vaccine development. In response, organizations are prioritizing inventory buffers, dual-sourcing agreements, and strategic partnerships that hedge against tariff volatility while maintaining pathways for rapid technology transfer and scale-up.

Deep segmentation insights connecting vaccine platforms, age cohorts, channels, end users, and administration routes to inform differentiated development and delivery strategies

Segmentation analysis reveals multiple axes that determine how vaccines are developed, positioned, and delivered. Based on vaccine type, stakeholders must weigh the distinct scientific and logistical characteristics of conjugate vaccines, inactivated vaccines, live attenuated vaccines, mRNA vaccines, subunit vaccines, and viral vector vaccines, recognizing that each platform presents unique implications for manufacturing complexity, cold chain requirements, and immunogenicity profiles. Based on age group, program design must account for adult, geriatric, and pediatric cohorts, with adults further differentiated into middle aged, older adult, and young adult subsegments; geriatrics subdivided into elderly and senior groups; and pediatrics parsed into adolescent, child, infant, and toddler populations, since immunologic maturity and risk-benefit assessments vary markedly by subgroup and inform dose scheduling and co-administration strategies.

Based on distribution channel, the selection between direct purchase, hospital pharmacy, online pharmacy, and retail pharmacy pathways matters greatly, with online pharmacy activity split between mobile app sales and website sales and retail pharmacy provision differentiated between chain pharmacy and independent pharmacy outlets; these distinctions influence consumer access patterns, digital engagement strategies, and reconciliation processes for vaccination records. Based on end user, the choice among clinics, home care, hospitals, and research institutes-and the further split of hospitals into government and private institutions-affects procurement cadence, cold chain expectations, and reporting obligations. Finally, based on route of administration, the intramuscular, intranasal, oral, and subcutaneous options carry implications for clinician training, patient acceptance, and administration settings.

Taken together, these segmentation dimensions intersect to define tailored product development pathways and commercialization approaches. For instance, a subunit vaccine intended for infants and administered intramuscularly through clinic-based programs will require a different packaging, dosing, and outreach strategy than an intranasal formulation targeting adolescents distributed through retail pharmacies. Therefore, market entry and scale strategies must be predicated on multidimensional segmentation that aligns scientific attributes with delivery infrastructure and payer expectations.

Region-specific dynamics and infrastructure factors that determine how vaccine innovation translates into access, adoption, and public health outcomes across global markets

Regional dynamics shape both demand patterns and operational constraints, producing distinct opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced cold-chain infrastructure and high regulatory capacity enable rapid adoption of complex platforms, though regional inequities and payer fragmentation require tailored reimbursement strategies and flexible distribution models. In contrast, parts of Europe, Middle East & Africa face variable infrastructure and procurement heterogeneity, which elevates the importance of regional coordination mechanisms and technology transfer initiatives to strengthen manufacturing and distribution resilience.

In the Asia-Pacific region, a mix of high-volume manufacturing capability and large, diverse populations creates both scale advantages and complex market access challenges. Rapid urbanization and strong private-sector delivery channels support innovative distribution pilots, but rural access and regulatory harmonization remain persistent hurdles. Across all regions, established immunization programs and existing public health partnerships provide scaffolding for scaled rollout, yet differences in cold chain reach, digital health adoption, and local clinical practice patterns require regionally adapted strategies.

As a consequence, stakeholders should consider differentiated approaches that leverage regional strengths-such as manufacturing capacity in parts of the Asia-Pacific and advanced payer systems in North America-while investing in capacity building where gaps threaten equitable access. Strategic investments in regional supply hubs, harmonized regulatory pathways, and interoperable surveillance systems will be key to translating vaccine innovation into broad population health impact.

Corporate strategies and partnership models spotlighting how manufacturers, platform innovators, and manufacturing partners jointly advance development, scale, and access

Company-level dynamics in the respiratory vaccine space reflect a blend of competition and collaboration. Established large-scale biologics manufacturers continue to invest in platform diversification, leveraging broad regulatory experience and manufacturing scale to de-risk advanced clinical programs. At the same time, specialized platform innovators, particularly those focused on mRNA or novel adjuvant systems, are driving rapid antigen redesign capabilities and flexible production models that support iterative updates and multivalent constructs.

Contract development and manufacturing organizations have become strategic partners rather than mere vendors; their capabilities in single-use technology, fill-finish capacity, and regulatory support enable faster commercial scale-up for smaller developers. Collaboration between originators and regional manufacturers is also expanding, often framed as risk-sharing or technology transfer arrangements that extend capacity while addressing local access goals. Additionally, diagnostic and digital health firms are creating adjacent value by enabling precision deployment, streamlined post-market surveillance, and improved uptake tracking.

From a strategic perspective, successful companies demonstrate a balanced portfolio approach that pairs short-path commercial opportunities with longer-term platform investments. They also prioritize supply chain redundancy and geographic diversification to mitigate policy and logistics risk. Finally, transparency in clinical data sharing and proactive engagement with regulators and public health bodies enhances credibility and shortens the path to broad adoption, particularly when new platforms are entering population-scale programs.

Practical, high-impact recommendations for senior leaders to accelerate vaccine innovation, secure resilient supply chains, and expand equitable access across regions and populations

Industry leaders should pursue a coordinated strategy that aligns scientific prioritization with resilient supply chain design and proactive policy engagement. First, prioritize platform agility: invest in modular manufacturing and platform-agnostic skills that permit rapid antigen swaps and multivalent product development, while ensuring robust quality systems and regulatory documentation that facilitate accelerated reviews. Second, strengthen supply chain resilience by diversifying suppliers for critical inputs, establishing regional buffer inventories, and forging long-term agreements with contract manufacturers to reduce single-point failure risk.

Third, engage regulators and payers early and continuously to define evidence expectations, real-world data requirements, and reimbursement frameworks that support uptake across age segments and delivery settings. Fourth, design distribution strategies that incorporate both traditional clinical channels and emerging digital and pharmacy-led pathways, optimizing for ease of access and vaccination record integration. Fifth, commit to capacity building and equitable access through technology transfer, regional partnerships, and training programs that support local production and distribution capabilities.

Finally, leaders should make data transparency a differentiator: invest in post-market surveillance systems and real-world effectiveness studies that not only satisfy regulatory requirements but also inform iterative product improvements and targeted public health interventions. By integrating these elements into a cohesive plan, organizations can convert scientific promise into durable public health value while navigating regulatory, commercial, and geopolitical complexity.

A transparent, reproducible research methodology integrating literature review, expert interviews, and cross-validated operational analysis to underpin the study findings

This analysis synthesizes primary and secondary inputs through a structured, reproducible methodology that combines literature synthesis, expert consultation, and cross-validation against operational datasets. The literature synthesis encompassed peer-reviewed clinical data, regulatory guidance documents, and public health communications to establish the scientific and policy context. Expert consultation included interviews with clinical investigators, manufacturing and supply chain leads, regulatory affairs specialists, and immunization program managers to capture practical implementation insights and operational constraints.

Quantitative inputs were assessed to identify patterns in manufacturing lead times, cold chain requirements, and distribution channel dynamics, and these inputs were triangulated with qualitative findings to ensure external validity. Where applicable, scenario analysis was used to examine the implications of supply chain disruptions and policy changes, with sensitivity checks to highlight the most robust strategic conclusions. All methodological choices, inclusion criteria, and limitations are documented to support reproducibility and to help readers understand the confidence bounds around key findings.

Importantly, the methodology emphasizes transparency and triangulation: every major assertion is linked to at least two independent evidence streams or to direct expert corroboration, and assumptions used in scenario exercises are explicitly stated to support critical review. This approach supports both decision-grade insight and practical action planning for stakeholders across the development, manufacturing, and policy spectrum.

A conclusive synthesis stressing the need to combine technological flexibility, supply chain resilience, and policy engagement to realize public health impact from vaccine innovation

The convergent trends of platform maturation, regulatory adaptation, and shifting distribution models create an inflection point for respiratory disease prevention. Technology advances, especially in modular platforms and adjuvant science, expand the set of feasible product profiles and create opportunities to target multiple pathogens or broaden durability. At the same time, supply chain fragilities and policy shifts require organizations to embed resilience into strategic planning through supplier diversification, regional partnerships, and investment in scalable manufacturing modalities.

Policy and payer engagement emerge as decisive levers for uptake: transparent value articulation and an evidence strategy that addresses both efficacy and real-world performance are essential to secure broad adoption across age cohorts and care settings. Furthermore, segmentation-driven product and channel design will determine the practical reach of innovations, with pediatric and geriatric strategies needing distinct clinical and operational considerations. Finally, equitable access is not only an ethical imperative but a practical requirement for pandemic preparedness; strengthening regional manufacturing and facilitating technology transfer are therefore central to long-term global health security.

In sum, stakeholders who integrate technological flexibility, operational resilience, and policy foresight will be best positioned to translate vaccine innovation into sustainable public health impact and organizational value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of mRNA technology to accelerate development of universal RSV vaccines
• 5.2. Expansion of adjuvant formulations to enhance immunogenicity in elderly populations with influenza vaccines
• 5.3. Regulatory progression of next-generation intranasal COVID-19 vaccines for mucosal immunity
• 5.4. Investment in combination vaccines targeting multiple respiratory pathogens to streamline immunization schedules
• 5.5. Adoption of nanoparticle-based delivery systems to improve stability and efficacy of pediatric RSV vaccines
• 5.6. Clinical trial advancements in pan-coronavirus vaccines addressing emerging SARS-CoV-2 variants
• 5.7. Emergence of thermostable vaccine formulations reducing cold chain dependency in global immunization campaigns
• 5.8. Government funding initiatives supporting universal influenza vaccine research with broad cross-strain protection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Disease Vaccine Market, by Vaccine Type

• 8.1. Conjugate Vaccine
• 8.2. Inactivated Vaccine
• 8.3. Live Attenuated Vaccine
• 8.4. MRNA Vaccine
• 8.5. Subunit Vaccine
• 8.6. Viral Vector Vaccine

9. Respiratory Disease Vaccine Market, by Age Group

• 9.1. Adult
  • 9.1.1. Middle Aged
  • 9.1.2. Older Adult
  • 9.1.3. Young Adult
• 9.2. Geriatric
  • 9.2.1. Elderly
  • 9.2.2. Senior
• 9.3. Pediatric
  • 9.3.1. Adolescent
  • 9.3.2. Child
  • 9.3.3. Infant
  • 9.3.4. Toddler

10. Respiratory Disease Vaccine Market, by Distribution Channel

• 10.1. Direct Purchase
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
  • 10.3.1. Mobile App Sales
  • 10.3.2. Website Sales
• 10.4. Retail Pharmacy
  • 10.4.1. Chain Pharmacy
  • 10.4.2. Independent Pharmacy

11. Respiratory Disease Vaccine Market, by End User

• 11.1. Clinics
• 11.2. Home Care
• 11.3. Hospitals
  • 11.3.1. Government Hospitals
  • 11.3.2. Private Hospitals
• 11.4. Research Institutes

12. Respiratory Disease Vaccine Market, by Route Of Administration

• 12.1. Intramuscular
• 12.2. Intranasal
• 12.3. Oral
• 12.4. Subcutaneous

13. Respiratory Disease Vaccine Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Respiratory Disease Vaccine Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Respiratory Disease Vaccine Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Pfizer Inc.
  • 16.3.2. GlaxoSmithKline plc
  • 16.3.3. Sanofi S.A.
  • 16.3.4. Seqirus Pty Ltd
  • 16.3.5. Moderna, Inc.
  • 16.3.6. AstraZeneca plc
  • 16.3.7. Johnson & Johnson
  • 16.3.8. Novavax, Inc.
  • 16.3.9. BioNTech SE
  • 16.3.10. Sinovac Biotech Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MIDDLE AGED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY OLDER ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY YOUNG ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SENIOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TODDLER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY MOBILE APP SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY WEBSITE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GOVERNMENT HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 245. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 246. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 247. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 248. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 249. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 250. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 251. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
• TABLE 252. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2025-2032 (USD MILLION)
• TABLE 253. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
• TABLE 254. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
• TABLE 255. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 256. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
• TABLE 257. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 258. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 272. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 273. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 274. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 275. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
• TABLE 276. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2025-2032 (USD MILLION)
• TABLE 277. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
• TABLE 278. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
• TABLE 279. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
• TABLE 280. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
• TABLE 281. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 282. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 283. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
• TABLE 284. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
• TABLE 285. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
• TABLE 286. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
• TABLE 287. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
• TABLE 290. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
• TABLE 291. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 292. NORTH AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 293. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 294. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 295. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
• TABLE 296. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
• TABLE 297. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 298. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 299. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
• TABLE 300. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT, 2025-2032 (USD MILLION)
• TABLE 301. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2018-2024 (USD MILLION)
• TABLE 302. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY GERIATRIC, 2025-2032 (USD MILLION)
• TABLE 303. LATIN AMERICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PEDIA